What the research shows
A multicenter pediatric study enrolled 110 children with growth hormone deficiency and included 86 in its efficacy analysis. Researchers observed faster linear growth during the first year compared with the children's pretreatment growth rates. The comparison was with their own earlier growth. Geref International Study Group.
The FDA recorded the discontinuation of two Geref presentations. It determined that safety or effectiveness concerns were not the reason for their withdrawal from sale. FDA determination on Geref.
Documented formats
The FDA notice describes distinct historical sermorelin acetate injection presentations in vials and ampoules for treatment and diagnostic use.
Testing and purity
Confirm the 29-residue amidated peptide and its acetate form. Record whether a quantity is expressed as sermorelin base or as the acetate salt.
How to read a batch reportQuestions about Sermorelin
What did the diagnostic presentation test?
It was used to assess whether the pituitary could release growth hormone in response to a signal.
Did the pediatric growth study examine adult aging?
It followed growth in children with growth hormone deficiency. Adult body composition and aging outcomes fall outside that study.